Table 3.
Expression of SST2A and SST3 in screening group, represented by less than 20 cores.
| Diagnosis | TMA ID | SST2A+/3– % (n) | SST3+/2A– % (n) | SST2A+/3+ % (n) | SST2A–/3– % (n) |
|---|---|---|---|---|---|
| Plasma cell myeloma (n = 18) | BO2081 | 11.1% (2) | 5.6% (1) | 50.0% (9) | 33.3% (6) |
| Atypical carcinoid (n = 18) | NE841 | 0.0% (0) | 33.3% (6) | 0.0% (0) | 66.7% (12) |
| Renal carcinomas (n = 16) | KD2001 | 0.0% (0) | 31.3% (5) | 31.3% (5) | 37.5% (6) |
| Neuroendocrine adenocarcinoma (n = 15) | NE841 | 0.0% (0) | 20.0% (3) | 20.0% (3) | 60.0% (9) |
| Adamantioma (n = 12) | BO2081 | 0.0% (0) | 50.0% (6) | 0.0% (0) | 50.0% (6) |
| Aneurismal bone cyst (n = 12) | BO2081 | 0.0% (0) | 83.3% (10) | 16.7% (2) | 0.0% (0) |
| Adrenal cortical adenocarcinoma (n = 9) | AG801 | 0% (0) | 33.3% (3) | 1.1% (1) | 55.5% (5) |
| Benign osteochondroma (n = 6) | BO2081 | 0.0% (0) | 66.7% (4) | 0.0% (0) | 33.3% (2) |
| Metastatic cholangiocarcinoma (n = 4) | LV1221 | 100% (4) | 0.0% (0) | 0% (0) | 0.0% (0) |
| Osteofibrous dysplasia (n = 5) | BO2081 | 0.0% (0) | 100.0% (5) | 0.0% (0) | 0% (0) |
| Breast invasive carcinoma (n = 4) | TP242f | 0.0% (0) | 50.0% (2) | 25.0% (1) | 25.0% (1) |
| Lung carcinomas (n = 4) | TP242f | 25.0% (1) | 75.0% (3) | 0.0% (0) | 0.0% (0) |
| Prostate adenocarcinoma (n = 4) | TP242f | 0.0% (0) | 25.0% (1) | 0.0% (0) | 75.0% (3) |
| Colon adenocarcinoma (n = 4) | TP242f | 50.0% (2) | 25.0% (1) | 0.0% (0) | 25.0% (1) |
| Lung small cell carcinoma (n = 4) | NE841 | 0.0% (0) | 75.0% (3) | 0.0% (0) | 25.0% (1) |
| Mixed HCC (n = 4) | LV1221 | 0.0% (0) | 50.0% (2) | 0.0% (0) | 50.0% (2) |
| Chondroma (n = 4) | BO2081 | 75.0% (3) | 0.0% (0) | 0.0% (0) | 25.0% (1) |
| Chordoma (malignant) (n = 4) | BO2081 | 0.0% (0) | 0.0% (0) | 0.0% (0) | 100.0% (4) |
| Ewing’s sarcoma (n = 4) | BO2081 | 25.0% (1) | 25.0% (1) | 25.0% (1) | 25.0% (1) |
| Bone squamous cell carcinoma (n = 4) | BO2081 | 0.0% (0) | 75.0% (3) | 0.0% (0) | 25.0% (1) |
| Mediastinum squamous cell carcinoma (n = 2) | NE841 | 100.0% (2) | 0.0% (0) | 0.0% (0) | 0.0% (0) |
| Adenosquamous carcinoma of liver (n = 2) | LV1221 | 0.0% (0) | 0.0% (0) | 0.0% (0) | 100.0% (2) |
| Chondroblastoma (n = 2) | BO2081 | 0.0% (0) | 100.0% (2) | 0.0% (0) | 0.0% (0) |
| Osteoblastoma (malignant) (n = 2) | BO2081 | 0.0% (0) | 0.0% (0) | 0.0% (0) | 100.0% (2) |
Numbers indicate the number of cores found utilitarianly positive for the respective receptor expression (IRS ≥ 6). The co-expression has been determined when both receptors on the same core were positive (IRS ≥ 6).